文献速递心律失常血脂与心血管预防

口服抗凝药与心房颤动患者肝损伤风险的前瞻性研究

Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation.
PubMed 文献 · Heart · 2017-01-05

本研究基于MarketScan数据库纳入113 717例心房颤动患者,比较启动直接口服抗凝药(DOAC)或华法林后肝损伤住院风险。中位随访12个月,共960例肝损伤住院。多因素校正后,达比加群、利伐沙班和阿哌沙班启动者肝损伤住院风险均低于华法林,其中达比加群风险最低;利伐沙班启动者风险较达比加群启动者增加56%。

要点

  • 与华法林相比,达比加群、利伐沙班和阿哌沙班启动者肝损伤住院风险均更低,达比加群最低。
  • 利伐沙班启动者肝损伤住院风险较达比加群启动者增加56%(HR 1.56,95%CI 1.22至1.99)。
  • 既往肝、胆囊和肾脏疾病、癌症、贫血、心力衰竭和酒精中毒显著预测肝损伤住院。

核心结论

  • 在非瓣膜性心房颤动患者中,与华法林相比,DOAC与肝损伤住院风险降低相关,其中达比加群风险最低。

研究设计与样本

  • 研究纳入MarketScan Commercial and Medicare Supplemental数据库中2011年11月4日后首次开具口服抗凝药处方的113 717例心房颤动患者(平均年龄70岁,39%女性),随访至2014年12月31日。
  • 其中56 879例启动华法林,17 286例启动达比加群,30 347例启动利伐沙班,9205例启动阿哌沙班;肝损伤住院和合并症通过医疗索赔数据识别。

主要发现

  • 中位随访12个月期间,共识别960例肝损伤住院。
  • 肝损伤住院率(每1000人年)分别为:华法林9.0,达比加群4.0,利伐沙班6.6,阿哌沙班5.6。
  • 多因素校正后,与华法林相比,达比加群启动者肝损伤住院风险HR为0.57(95%CI 0.46至0.71),利伐沙班为0.88(95%CI 0.75至1.03),阿哌沙班为0.70(95%CI 0.50至0.97)。
  • 与达比加群启动者相比,利伐沙班启动者肝损伤住院风险增加56%(HR 1.56,95%CI 1.22至1.99)。
  • 除抗凝药类型外,既往肝、胆囊和肾脏疾病、癌症、贫血、心力衰竭和酒精中毒显著预测肝损伤住院;包含这些变量的预测模型具有足够的区分能力(C统计量0.67,95%CI 0.64至0.70)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the risk of liver injury hospitalisation in patients with atrial fibrillation (AF) after initiation of direct oral anticoagulants (DOACs) or warfarin and to determine predictors of liver injury hospitalisation in this population. METHODS: We studied 113 717 patients (mean age 70, 39% women) with AF included in the MarketScan Commercial and Medicare Supplemental databases with a first prescription for oral anticoagulation after 4 November 2011, followed through 31 December 2014. Of these, 56 879 initiated warfarin, 17 286 initiated dabigatran, 30 347 initiated rivaroxaban and 9205 initiated apixaban. Liver injury hospitalisation and comorbidities were identified from healthcare claims. RESULTS: During a median follow-up of 12 months, 960 hospitalisations with liver injury were identified. Rates of liver injury hospitalisation (per 1000 person-years) by oral anticoagulant were 9.0 (warfarin), 4.0 (dabigatran), 6.6 (rivaroxaban) and 5.6 (apixaban). After multivariable adjustment, liver injury hospitalisation rates were lower in initiators of DOACs compared with warfarin: HR (95% CI) of 0.57 (0.46 to 0.71), 0.88 (0.75 to 1.03) and 0.70 (0.50 to 0.97) for initiators of dabigatran, rivaroxaban, and apixaban, respectively (vs. warfarin). Compared with dabigatran initiators, rivaroxaban initiators had a 56% increased risk of liver injury hospitalisation (HR 1.56, 95% CI 1.22 to 1.99). In addition to type of anticoagulant, prior liver, gallbladder and kidney disease, cancer, anaemia, heart failure and alcoholism significantly predicted liver injury hospitalisation. A predictive model including these variables had adequate discriminative ability (C-statistic 0.67, 95% CI 0.64 to 0.70). CONCLUSIONS: Among patients with non-valvular AF, DOACs were associated with lower risk of liver injury hospitalisation compared with warfarin, with dabigatran showing the lowest risk.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Alonso A, MacLehose RF, Chen LY, et al. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. Heart. 2017. PMID: 28057799. doi:10.1136/heartjnl-2016-310586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。